Day One Biopharma's OJEMDA Receives Positive EU Regulatory Opinion; Projects $225-250M Revenue in 2026
DAWN sits 88% above its 52-week low of $5.635.
Summary
Day One Biopharmaceuticals announced a significant positive development for its lead drug, OJEMDA, with the Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion for conditional marketing authorization in Europe. This recommendation is a critical step towards expanding OJEMDA's market access beyond the U.S. The company also reiterated robust 2026 U.S. net product revenue guidance of $225-250 million, indicating over 50% growth from 2025's $155.4 million. This combination of a major regulatory milestone for international expansion and strong financial guidance is highly material, signaling a positive outlook for the company's growth and product commercialization. Investors will be closely monitoring the final European approval and the company's progress towards achieving its revenue targets.
At the time of this announcement, DAWN was trading at $10.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.64 to $13.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Unknown.